MyFinsight
Home
Blog
About
Contact
Download
Download image
Net (decrease)
increase in cash and cash...
-$28,434,596
Accrued expenses and
other current...
$4,186,161
Research and development
expense, acquired in...
$2,000,000
Share-based compensation
expense
$1,331,080
Prepaid expenses and
other current assets
-$1,107,686
Accounts payable
$1,095,967
Reduction in the carrying
amount of operating...
$108,406
Depreciation and
amortization expense
$16,251
Cash used in
operating activities
-$26,385,380
Cash used in
investing activities
-$2,033,948
Cash (used in)
provided by financing...
-$15,268
Canceled cashflow
$9,845,551
Net loss
-$36,123,615
Acquired in-process
research and development
$2,000,000
Purchase of property and
equipment
$33,948
Payment of offering
costs from the sale of...
$15,268
Operating lease liability
-$107,316
Back
Back
Cash Flow
source: myfinsight.com
Context Therapeutics Inc. (CNTX)
Context Therapeutics Inc. (CNTX)